Population pharmacokinetic and pharmacodynamic analysis in allergic diseases

被引:4
作者
Lovern, Mark [2 ]
Sargentini-Maier, Maria-Laura [1 ]
Otoul, Christian [1 ]
Watelet, Jean-Baptiste [3 ]
机构
[1] UCB Pharma SA, Pharmacometr, Braine Lalleud, Belgium
[2] GlaxoSmithKline, Raleigh, NC USA
[3] Univ Ghent, Dept Otorhinolaryngol, B-9000 Ghent, Belgium
关键词
Allergy; asthma; population; PKPD; NLME modelling; meta-analysis; COMPUTER-CONTROLLED INFUSION; PHASE-I; MODEL; CHILDREN; PARAMETERS; LEVOCETIRIZINE; CETIRIZINE; KINETICS; PUMP;
D O I
10.1080/10837450902891543
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In this chapter, we introduce the concepts and methodologies of population analysis as applied to analyzing pharmacokinetic and pharmacodynamic data. One of the key determining characteristics of the population approach is that through it, one seeks not only to characterize deterministic trends in the data, but also to identify and estimate the magnitudes of the important sources of variability within the data. The first section of this chapter provides an introduction to the primary concepts of, and motivation for, population modeling by way of a hypothetical case study. Then, the various methodologies that have been employed throughout the history of population analysis are described in further detail. Of these, the most commonly employed today is nonlinear mixed-effects (NLME) modeling. Finally, notable examples of the application of population PK and PK/PD modeling to treatments for allergies and asthma are discussed. Population PK models have frequently been used to extrapolate exposures to special populations, such as pediatrics, as well as to optimize treatment regimens and trial designs for these populations. Population PK/PD models have most frequently been applied to analyzing and interpreting data from wheal and flare trials, but are also becoming increasingly important in the analysis of PD data from monoclonal antibodies.
引用
收藏
页码:475 / 485
页数:11
相关论文
共 36 条
[1]   Role of modelling and simulation in Phase I drug development [J].
Aarons, L ;
Karlsson, MO ;
Mentré, F ;
Rombout, F ;
Steimer, JL ;
van Peer, A .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 13 (02) :115-122
[2]  
[Anonymous], GUID IND POP PHARM
[3]  
*AV PHARM, 2005, ALL D FEX HYDR PSEUD
[4]  
Awni Walid, 1995, Pharmaceutical Research (New York), V12, pS362
[5]   Applications of population pharmacokinetics in current drug labelling [J].
Duan, J. Z. .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2007, 32 (01) :57-79
[6]   Analysis of population pharmacokinetic data using NONMEM and WinBUGS [J].
Duffull, SB ;
Kirkpatrick, CMJ ;
Green, B ;
Holford, NHG .
JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2005, 15 (01) :53-73
[7]  
DUFFULL SB, 2007, PHARMACOMETRICS SCI
[8]   COMPUTER-CONTROLLED INFUSION OF INTRAVENOUS DEXMEDETOMIDINE HYDROCHLORIDE IN ADULT HUMAN VOLUNTEERS [J].
DYCK, JB ;
MAZE, M ;
HAACK, C ;
AZARNOFF, DL ;
VUORILEHTO, L ;
SHAFER, SL .
ANESTHESIOLOGY, 1993, 78 (05) :821-828
[9]  
*EMEA, 2006, EMEACHMPEWP185990200
[10]   A pharmacokinetic/pharmacodynamic model for a platelet activating factor antagonist based on data arising from Phase I studies [J].
Evans, L ;
Aarons, L ;
Brearley, C .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2005, 57 (02) :183-189